In short
Envudeucitinib, also known as ESK-001, is a promising new drug being studied for the treatment of moderate to severe plaque psoriasis. This article explores the ongoing clinical trials investigating the effectiveness and safety of this medication compared to placebo and an active comparator, apremilast. We'll discuss the trial design, eligibility criteria, and expected outcomes of this important research.
At a glance
- Drug Name
- Envudeucitinib (ESK-001)
- Condition Studied
- Moderate to Severe Plaque Psoriasis
- Trial Phase
- Phase 3
- Main Objective
- Determine if ESK-001 is superior to placebo at Week 16
- Secondary Objectives
- Compare ESK-001 to apremilast, assess safety and tolerability, characterize pharmacokinetics
- Trial Duration
- 24 weeks (16-week Treatment Period + 8-week Maintenance Period)
- Dosage
- 40 mg twice daily
- Primary Endpoints
- Achievement of PASI-75 & sPGA-0/1 at Week 16 compared to Placebo
- Key Inclusion Criteria
- Adults ≥18 years, plaque psoriasis for ≥6 months, ≥10% BSA affected, PASI ≥12, sPGA ≥3
- Key Exclusion Criteria
- Non-plaque psoriasis, recent serious infections, immunodeficiency, certain lab abnormalities, recent use of specific psoriasis treatments
What is ENVUDEUCITINIB?
ENVUDEUCITINIB, also known as ESK-001 or FTP-637, is a new medication being studied for the treatment of moderate to severe plaque psoriasis. Plaque psoriasis is a chronic skin condition characterized by red, scaly patches on the skin that can be itchy and painful.
This drug is currently undergoing a Phase 3 clinical trial, which is an advanced stage of testing to determine its effectiveness and safety in treating psoriasis.
How Does It Work?
ENVUDEUCITINIB belongs to a class of drugs known as TYK2 inhibitors. TYK2 stands for Tyrosine Kinase 2, which is an enzyme involved in the inflammatory processes that contribute to psoriasis. By inhibiting this enzyme, ENVUDEUCITINIB may help reduce inflammation and improve psoriasis symptoms.
Clinical Trial Details
The ongoing clinical trial, named ONWARD1, is designed to evaluate how well ENVUDEUCITINIB works compared to a placebo (a substance with no active ingredients) and another psoriasis medication called apremilast.
Key points about the trial:
- It's a multicenter, randomized, double-blind study. This means it's being conducted at multiple locations, participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know who is receiving which treatment.
- The trial lasts for 24 weeks, with the primary evaluation point at 16 weeks.
- Participants take the medication orally (by mouth) twice daily.
Who Can Participate in the Trial?
The trial is open to adults (18 years and older) with moderate to severe plaque psoriasis. Some key eligibility criteria include:
- Having had plaque psoriasis for at least 6 months
- Psoriasis plaques covering at least 10% of the body surface area
- A certain level of psoriasis severity as measured by standard scales (PASI and sPGA)
However, there are also several conditions that would exclude someone from participating, such as having certain other medical conditions or having used specific psoriasis treatments recently.
Potential Benefits
The main goals of the study are to determine if ENVUDEUCITINIB can:
- Improve psoriasis symptoms better than a placebo
- Work as well as or better than apremilast, an existing psoriasis treatment
- Reduce the area of skin affected by psoriasis
- Improve quality of life for people with psoriasis
- Reduce itching associated with psoriasis
Safety Considerations
As with any new medication, safety is a crucial aspect of the study. The researchers will be closely monitoring participants for any side effects or adverse reactions throughout the trial.
It's important to note that because this is an investigational drug, not all potential side effects may be known at this time. This is why careful monitoring and reporting of any health changes during the trial is crucial.
If ENVUDEUCITINIB proves to be safe and effective in this trial, it could potentially offer a new treatment option for people with moderate to severe plaque psoriasis in the future.